Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders

Area of Science:

• Neuropsychopharmacology
• Medicinal Chemistry
• Neuroscience

Background:

• The serotonergic system is crucial for mood, cognition, and behavior.
• Selective serotonin reuptake inhibitors (SSRIs) have limitations including receptor heterogeneity and desensitization.
• Dual modulation of serotonin (5-HT) receptor subtypes presents a promising therapeutic strategy.

Purpose of the Study:

• To review progress in developing dually acting compounds for central nervous system (CNS) disorders.
• To highlight clinically relevant examples and experimental ligands.
• To discuss challenges and future directions in rational dual modulation.

Main Methods:

• Literature review of dually acting serotonergic agents.
• Analysis of structure-activity relationships and clinical findings.
• Exploration of advanced techniques like biased signaling and optopharmacology.

Main Results:

• Several dually acting compounds are clinically relevant or in development for CNS disorders.
• Examples include ligands targeting 5-HT1A/5-HT2A, 5-HT2A/5-HT2C, and 5-HT1A/5-HT1B receptors.
• Novel approaches like biased signaling and optopharmacology show potential for future drug design.

Conclusions:

• Dually acting serotonergic ligands offer potential for superior therapeutic outcomes in CNS disorders.
• Rational design of these agents requires integration of pharmacology and clinical data.
• Advances in signaling and drug delivery may lead to more effective and safer treatments.